|
A non-invasive-cancer-test startup a day keeps the FOMO away.
|
Startup of the Year: Daily Dealflow
Startup of the Year discovers and supports the most promising and innovative startups from around the world through #DailyDealflow, our Podcast & more.
Oct. 15 -16 | Memphis, TN
|
RUBYnanomed
RUBYnanomed for the non-invasive monitoring of cancer. Catching all the cancer cells with microfluidics for liquidbiopsy.
|
|
RUBYnanomed has developed and can manufacture the RUBYchip®, a microfluidic device for isolating all types of CTCs (independently of their phenotype) from unprocessed whole blood. In this way, RUBYnanomed offers a non-invasive and real-time snapshot of cancer progression to oncologists.
The second product in our pipeline, provides an easy-to-use automated platform to retrieve cancer information at any time point through a blood draw. Our automated system prepares the isolated cells for reading and sends out a report describing the type and number of cancer cells found in the sample and their expression of selected biomarkers, pinpointing possible routes of therapy.
In a first preliminary clinical test, we demonstrated the higher efficiency and sensitivity of our cartridge against the reference CellSearch® equipment in a small pool of 9 metastatic colorectal cancer patients. We were able to isolate a higher number of CTCs from unprocessed whole blood samples, and showed the potential to provide improved correlation with clinical prognostic information (Scientific Reports- in press).
Currently, RUBYnanomed is running pre-clinical trials at 8 hospitals for 5 different types of cancer in different countries in Europe.
In the short life of this startup, they won several prizes at different accelerators in Portugal and Germany.
|
What's Innovative About Their Solution?
The RUBYnanomed technology is based on microfluidics and microengineering. The solutions available in the market are mostly based on the use of magnetic particles for the isolation of CTCs, using membrane proteins expressed on the CTCs. In this way, the isolation is biased, and not all cells are isolated, only the ones expressing that specific receptor. Also, the other system fixate the cells, and they are not viable any more. The RUBYchip isolates viable cells with no need of any sample pre-treatment. Further, our automated reader provides an unbiased analysis platform independent on laboratory or user, which will provide oncologists with comparable data at different hospitals.
In summary, the competitive advantages offered by RUBYnanomed are:
• All CTCs are isolated independently of their expression – epithelial and mesenchymal
• Isolated CTCs are viable: functional studies, drug dose studies, genomic studies can be performed.
• 8 times more sensitivity than approved FDA standard
• Fast and no need of sample preparation
|
📍 Location
Braga, Portugal
|
|
⚙️ Product Stage
Functional Prototype
|
|
🏭 Industries
Biotech, Health & Wellness, Pharmaceuticals
|
|
|
🤑 Fundraising Status
Actively raising
|
|
💸 Total Funding
To Date
$0-100k
|
|
🙌 Founder Demographics
Female founder, Minority founder
|
|
|
Big Wins
- Involved in 3 preclinical trials and more than 5000 pre-orders for the RUBYchip.
- Participated in Shark Tank pitch at MIT - interest from Novartis
|
Contact the Founder:
Lorena Diéguez
|
|
Further Your Passion For Startups
The Startup of the Year Podcast raises the bar for startups around the world by providing further insight on the emerging companies featured in our Daily Dealflow newsletter and by highlighting newsworthy stories and global trends affecting the startup ecosystem. |
|
The Daily Dealflow is made possible thanks to the support of our amazing partners.
|
|
2019 Startup Outlook Report
SVB is pleased to present the 10th edition of our annual Startup Outlook Report, focusing on the innovation economies of the US, the UK, China and Canada. Read the report here.
|
|
|
Startup of the Year is powered by Established, a consultancy focused on helping organizations with their innovation, startup, and communication strategies.
Created by the talent responsible for building the Tech.Co brand (acquired by an international publishing company), we're leveraging decades of experience to help our collaborators further (or create) their brand & accomplish their most important goals.
|
|
Established, LLC is not a broker-dealer and cannot provide assurances and makes no representations or warranties as to the timing or price terms for any purchase or sale of early-stage company equity. Nothing contained in this email constitutes investment, legal, tax or other advice. No information or statements contained in this email should be relied upon in making an investment or different decision. You should review all risks and consult all applicable professionals when making any investment decisions. Information and statements contained within this email and any attachments are solely for informational purposes and does not constitute an offer to sell or a solicitation to buy any securities.
|
|
|
|
|
